Thiogenesis Therapeutics, Corp.TTI.V

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX-V · Canada · thiogenesis.com

Thiogenesis Therapeutics Corp. is a clinical-stage biopharmaceutical company headquartered in Toronto, Canada, developing thiol-based therapeutic compounds to treat unmet pediatric medical needs including inherited mitochondrial diseases. Its lead product candidate, TTI-0102, is a novel prodrug of cysteamine designed to reduce oxidative stress and restore mitochondrial function, with potential applications in MELAS, Leigh syndrome, and Rett syndrome.

Key ratios

ROA

-110.8%TTM

2024 -39.9%2023 -48.1%2022 -38.5%

ROE

-216.5%TTM

2024 -70.3%2023 -88.0%2022 -159.5%

Recent news

Thiogenesis Engages Brisco Capital for Investor Relations 2026-09-03 · Newsfile Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors 2026-06-17 · Newsfile Corp.Thiogenesis Closes Oversubscribed Non-Brokered Private Placement for Gross Proceeds of C$9.07 Million 2026-06-03 · Newsfile Corp.Thiogenesis Announces Non-Brokered Private Placement 2026-05-11 · Newsfile Corp.Thiogenesis Therapeutics to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference 2026-04-16 · Newsfile Corp.

Track TTI.V in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer